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CONFLICT OF INTEREST
The recognition that part of this variation in patient response may be genetic, and therefore potentially predictable, led to the development of numerous PGx tests to assess the presence or absence of known genetic variants to help predict an individual's response to drugs (5) . The results of these tests can help healthcare providers to select the most effective drug(s) and doses for a patient, inform drug development, and/or stratify participants in clinical trials (6, 7) .
Research studies have identified over 1000 human genes that may affect drug response (8) . Clinically relevant PGx interactions typically involve genes related to absorption, distribution, metabolism and excretion of a drug (ADME) (9) , or genes that encode drug targets and other proteins involved in the drug's mechanism of action. For example, non-ADME genes such as CFTR and VKORC1 are relevant to ivacaftor and warfarin response, respectively, and may be tested to guide therapeutic decision-making. In addition, genes encoding the human leukocyte antigens (HLA) are commonly tested for the variant HLA-B*57:01 to predict the likelihood of hypersensitivity reactions for abacavir (10) in patients seeking human immunodeficiency virus (HIV) antiretroviral therapy.
In 2015, about 150 different drugs that are approved by the US Food and Drug Administration (FDA) include pharmacogenetic information in the label, and only a few of them have recommendations for PGx testing (11) . Similarly, 155 drugs have PGx information in their Summary of Product Characteristics (SPC) as defined by the European Medicines Agency (EMA) (12) . Both the FDA label and the EMA SPC contain information ranging from references to pharmacokinetic genes or drug targets to requirements for genetic testing. However, labels mentioning genetic testing are rare and often associated with drugs for cancer treatment (e.g.
, EGFR/afatinib, ALK/crizotinib, KRAS/panitumumab).
Other examples of established gene/drug associations include HLA-B/abacavir, HLA-B/ carbamazepine, CYP2C19/clopidogrel, CYP2D6/Codeine, POLG/valproate, G6PD/ rasburicase, TPMT/thiopurines, and others. Although many of these drugs are widely prescribed (13) , for most of them PGx testing has yet to become common practice.
At the current time, clinical laboratories offer testing for a number of PGx genes, including CYP2C9, CYP2C19, CYP2D6, CYP3A4, CYP3A5, DPYD, HLA-B*57:01, SLCO1B1, VKORC1, and TPMT. The National Institutes of Health (NIH) Genetic Testing Registry (14, 15) lists over 280 PGx tests for about 160 drug responses. While some laboratories that offer these tests have reported good success with respect to feasibility and acceptance of genetic testing (16) , others have suggested that PGx tests are underutilized (17) (18) (19) . Lack of acceptance can arise when clinicians do not have sufficient knowledge of PGx tests, are unable to obtain the test results within an appropriate turn-around time (20) , are not sure whether there is sufficient evidence to support the use or reimbursement of PGx tests (20) (21) (22) , or cannot interpret and translate the genotype information into clinical actions (19, 23, 24) .
Ideally, test results and interpretations should be consistent regardless of which clinical laboratory performs the analysis. However, laboratories differ with respect to the PGx variants and haplotypes that are tested and the manner in which results are interpreted and communicated to the prescriber. This variability can have a significant impact on clinical decision-making, particularly because many genes involved in ADME and other aspects of pharmacology and toxicology can vary considerably among individuals and populations (25, 26) . As such, standardized nomenclature and transparency of variants tested and used for PGx haplotype definitions are needed to advance the adoption of pharmacogenetic testing by clinicians and to ensure that prescribers have essential information for appropriate treatment decisions.
Overview of Nomenclature for PGx Genes
Activity or function of enzymes, transporters or drug targets (pharmacogenetic phenotype) can be predicted by testing for one or more known sequence variants in PGx genes. Variants or combinations of variants in a gene that are linked together on a single chromosome define haplotypes. The terms haplotype, allele, and allelic variation are often used interchangeably. Results of PGx tests are commonly reported as diplotypes (or haplotype pairs) since human genes are present in two copies, except for genes located on the non-homologous parts of the X and Y chromosomes in males. However, haplotypes or diplotypes are typically assigned based on genotypes of tested genetic variants, and default assignments may be applied depending on whether these variants are detected. The summarization of observed variants into alleles/haplotypes facilitates the association of diplotypes with predicted phenotypes. Many PGx genes have greater clinical relevance when low-function variants are viewed as conferring recessive rather than co-dominant or dominant phenotypic effects, and prescribing guidelines often differ substantially for individuals carrying two variant alleles compared to those carrying only one dysfunctional allele.
Variants found during DNA sequence analysis or other types of genotyping tests used to diagnose inherited or somatic disorders are named using Human Genome Variation Society (HGVS) nomenclature (27) . The HGVS nomenclature had been designed specifically for use in clinical diagnostics and is currently the standard world-wide. Use of HGVS is recommended for clinical diagnostic reporting (28) . This nomenclature system describes variants with respect to a reference sequence, making the genomic position of the variant and the changes to the DNA, RNA and protein sequences comprehensible and less ambiguous to current and future users of the information. The HGVS nomenclature does not specify a specific reference sequence, thus the same variant could be described using different reference sequences, which might cause confusion.
Unlike other genes, a variety of nomenclature systems have been developed to describe allelic variation and haplotypes of ADME genes (29) . The most common is the "star" (*) system, which was implemented in the 1990s and has been widely adopted in the field. In most cases, *1 denotes the default reference (wild type or fully functional) allele or haplotype, while other designations (e.g. *2 or *3) define haplotypes carrying one or more variants (30) . The *1 allele definition is usually based on the subpopulation in which the gene was initially studied, and may not necessarily indicate the most common allele in all populations. In some cases, *1 is not the reference allele; for example, NAT2*4 is the reference allele for the NAT2 gene as it is the most common functional allele across human populations (31, 32) .
Laboratories report a variant if one or more allele-defining sequence variations are found and default to a reference allele (often, but not always *1) assignment in their absence. It should be noted that the reference allele designation is assigned depending on which variants were assayed and consequently excluded, but does not consider variants not included in the assay (i.e., an assigned *1 carrier may still have variants that the test was not designed to detect). In other words, a negative result for the alleles interrogated by the assay (and the designation of the *1 haplotype or reference allele) does not exclude the possibility that other dysfunctional alleles may be present. The probability that a *1 or reference allele default assignment is correct increases with the number of relevant sequence variations tested.
Lists of haplotypes and nomenclature for PGx genes can be found on a variety of gene or gene family specific websites that are usually maintained by specific nomenclature committees (Table 1 ). Information about PGx haplotypes is also available through more comprehensive sites, including the Pharmacogenomics Knowledge Base (PharmGKB) (33) . For many PGx genes (e.g. VKORC1), there are no nomenclature committees. In some instances, such SLCO1B1 (34) and ABCB1 (35) , tables summarizing variation have been published, but are not systematically maintained. Furthermore, variants of many PGx genes, including VKORC1, may be reported using more than one nomenclature system (36, 37) .
Rationale for Developing a Standard PGx Nomenclature
A major obstacle for the use of PGx information in clinical practice is the complexity of nomenclature systems and test designs, which can cause discrepancies in the predicted phenotype that is inferred from the genotype determined by the genetic test. Nomenclature differences contribute to difficulties reconciling genotype results for the same sample across laboratories (38, 39) and impede data analysis. Differences in test design can also lead to discordant diplotype results and ultimately incorrect phenotype predictions (Robert Freimuth, personal communication) . As such, a standardized PGx nomenclature system that clearly describes the variants identified as well as increased transparency about the test design are crucial to advance the adoption of PGx testing by clinicians.
Comparing PGx testing results from different laboratories can be challenging. For example, the Centers for Disease Control and Prevention's (CDC) Genetic Testing Reference Material Coordination Program (40) conducted projects to characterize genomic DNA samples from the Coriell Cell Repositories which can be used as reference materials for clinical PGx genetic testing (38, 39) . During the most recent study, nine volunteer clinical, research and commercial laboratories were provided with blinded genomic DNA samples which were tested for a number of PGx genes using a variety of different methods including single nucleotide variant (SNV) genotyping, copy number variant (CNV) assessment, and DNA sequence analysis.
The results of the GeT-RM study illustrate many inconsistencies due to different nomenclature systems and PGx test designs. The participating laboratories employed varying terms to describe SNV genotype results for 28 PGx genes. The star nomenclature system was used by some laboratories to describe alleles/haplotypes of many of the tested genes, while other laboratories utilized the predicted amino acid change or various other Kalman et notations and/or nomenclatures. In many cases, laboratories described the detected sequence variations using several different nomenclature systems for the same genes (e.g. VKORC1, Table 2 ).
Furthermore, the GeT-RM study found inconsistencies in reporting of genotype results. Some of the DNA sequencing assays made genotype calls from the coding strand while others made calls from the based on the non-coding strand using the Human Genome Reference Assembly as a guide. One test did not use the Human Genome Reference Assembly, but instead used sequences representing the major alleles identified during the Hap Map project ( Figure 1 ). These differences may not affect the actual results, but could impact the way in which results are represented and the depiction of variants in databases and scientific literature.
The tests performed in the GeT-RM study also showed little consistency in design. No two of the seven test panels detected the same set of SNVs/ haplotypes for any of the 28 PGx genes studied (39) . Different haplotype calls were often made for the same allele in a given sample, because not all tests were designed to detect the same haplotypes, as illustrated in Table 2 . In some cases these differences in test design can cause incorrect genotype assignments and phenotype prediction. As exemplified in Figure 2 , the CYP2C19 phenotype may not be accurately predicted when only a subset of relevant SNVs is tested. An intermediate metabolizer would be misclassified as an ultra-rapid or extensive metabolizer if rs28399504 (NG_008384.2:g.5001A>G, NM_00769.1:c.1A>G), which defines the CYP2C19*4 haplotype, was not tested.
Inconsistencies in nomenclature and design of assay panels create unnecessary complexity and make it difficult to compare data from different genotyping platforms. This has been observed in clinical proficiency testing surveys. Participants in the College of American Pathologists Pharmacogenetic Proficiency Survey (PGX) often reported inaccurate genotypes and phenotypes due to differences in test design (41) . For example, one of the CYP2D6 assays did not include any of the SNVs commonly used to identify the *41 allele.
The results from this test could cause this allele to be classified as normal function (*1) rather than reduced function (*41). In addition, approximately half of the tests in the study were not designed to detect the increased function allele CYP2C19*17, and incorrectly called the proficiency testing samples CYP2C19*1 (normal function) (41) .
Discrepancies may also arise due to the variable inclusion of methods to assess copy number variations. For example, tests that do not interrogate structural variants of CYP2D6 may report an individual with a CYP2D6*1/*2 haplotype as an extensive metabolizer, while another assay, that includes copy number assessment, may report the same genotype as an ultra-rapid metabolizer if a gene duplication is detected (e.g. CYP2D6*1/*2xN or *1xN/*2). These differences make it very difficult not only to understand genotype results, but also to compare results generated by different laboratories and/or tests. Such discrepancies may cause confusion, misinterpretation and incorrect results to be communicated; thus it is clear that standardized nomenclature, transparency of variants tested and unambiguous haplotype definitions are needed. (43), and PharmGKB.
To date, most PGx tests have evaluated the presence or absence of a defined set of known variants. However, next generation sequencing (NGS) is becoming more common in clinical and research laboratories and is also being applied to PGx testing. Sequence analysis will identify rare and/or novel variants with unknown or uncertain function that complicate not only allele designation and genotype calling, but also the prediction of phenotype (44) . Recent results from numerous whole genome and whole exome sequencing efforts (e.g. the NHLBI GO Exome Sequencing Project (45), revealed the presence of many rare variant alleles in genes relevant to drug metabolism and transport, often missense in nature, which are not included in the current PGx databases (46) . In addition, many more rare variants are expected to be identified during ongoing large population sequencing studies, including the 100,000 Genomes project in the UK and the 1-Million-Genomes Project in the US. Consideration of these rare variants will be required for the advancement of precision medicine initiatives. It will be difficult to develop new haplotype designations for these recently identified variants using the existing star or other nomenclature systems, and therefore, it may be desirable to modify or discontinue the use of star allele nomenclature and instead describe PGx variants with the same naming conventions and systems used for other genes (47) . It is expected that DNA sequencing of PGx associated genes will eventually become the standard method for genotype determination, which makes the creation of a standard variant naming format even more critical. 
CONSENSUS RECOMMENDATIONS FOR STANDARDIZATION OF PGx (ADME) NOMENCLATURE
To address the standardization of PGx nomenclature, the Centers for Disease Control and Prevention (CDC) organized an international workgroup to review current PGx nomenclature practices used to describe allelic variation of ADME PGx genes and facilitate translation between different nomenclature systems. Non-ADME genes, such as HLA, were excluded from the discussions. Ideas for mechanisms to increase the transparency of PGx test design were also discussed. Workgroup participants (summarized in 
Workgroup Recommendations
Current PGx nomenclature systems have been developed by domain experts, are widely accepted in PGx research communities, and have been commonly reported in the scientific literature. The workgroup agreed that the use of different nomenclature systems to describe PGx variants hinders communication and is not intuitive to clinicians, patients or researchers outside of the field. The group also acknowledged that PGx variants would be better reported in the context of the human genome assembly (as is the case with most non-PGx genes), especially as NGS applications are becoming more common. Because the current nomenclature is widely used in the PGx community, the workgroup did not recommend creating new nomenclature systems or abandoning current ones. Instead, they preferred to facilitate harmonization by clarifying sequence definitions of alleles. The workgroup recommended utilization of the Human Genome Variation Society nomenclature (27) for describing variants and haplotypes, and requiring transparency when reporting test results and describing underlying test methodologies. The workgroup suggested that for continuity and consistency with the literature, laboratories could also report star (*) alleles, or other legacy nomenclature, possibly as a side note on a report.
The following 9 recommendations (summarized in Table 4 ) take advantage of universally recognized and utilized systems for describing allelic variation.
3. Use a Locus Reference Genomic (LRG), RefSeqGene and/or a specific Human Genome Reference Assembly as a reference sequence. Both the reference sequence accession number and version number of the sequence should be indicated.
4.
Report rs IDs from dbSNP, when available.
The workgroup recommended utilizing widely accepted systems that are already in place for human genes, in particular the HGNC gene nomenclature (48, 49) , HGVS nomenclature and the Human Genome Reference Assembly (50). This will allow for transparent reporting of PGx variants to the clinical and research communities, facilitating incorporation of the data into existing human variation databases such as ClinVar and LOVD in a standardized manner. Use of fully qualified (reference sequence accession and version number indicated) HGVS nomenclature is recommended for submission of data to ClinVar as well as other databases.
The workgroup discussed ways to facilitate transition to the HGVS format from other nomenclature systems. The HGVS system requires description of variants relative to a reference sequence, which should be selected based on ability to support explicit (rather than inferred) representation, stable public access, comprehensiveness, and ease of use. Genomic sequences are recommended because intronic locations can be represented unambiguously. However, the exact genomic coordinates of such sequences are frequently updated as new information about the human genome is incorporated into the updated Human Genome Reference Assembly. These changes are versioned, and may alter the HGVS name of a variant which could cause confusion when results are compared over time. In order to reduce such misunderstandings, laboratories can include the latest HGVS nomenclature and the familiar or alternative names for the same variant in parenthesis.
The workgroup recognized that the genomic coordinates of the Human Genome Reference Assembly can be long, tedious and require noting the accession version number. Due to these challenges, the group recommended that HGVS notations could be made using a Locus Reference Genomic (LRG) (51, 52) RefSeqGene sequences, which are similar to LRGs, can also be used as reference sequences. RefSeqGene and LRG are tightly coordinated, and when an LRG is created it is equivalent to a version of a RefSeqGene. Chromosome sequences from the Human Genome Reference Assembly, and gene-specific sequences from RefSeqGene are based on the current version of the human genome assembly. RefSeqGenes and chromosome sequences are updated and versioned as novel genomic information becomes available; thus the version number must be reported for the unambiguous definition of these sequences.
Inclusion of dbSNP (54) reference SNP cluster identifiers (rs ID), each of which corresponds to a variant in a specific genomic location also provides a definition of each variant and allows reference to databases such as PharmGKB and ClinVar. rs IDs are available for the majority of commonly tested PGx variants and can be created upon request (55). In some cases, the variant described by the rs ID can refer to more than one sequence variant and may result in more than one haplotype designation. For example, the triallelic SNP rs5030865 (NG_008376.3:g.5959G>T, NM_000106.5:c.505G>T; NG_008376.3:g. 5959G>A, NM_000106.5:c.505G>A), defines haplotypes CYP2D6*8 and CYP2D6*14 depending on whether the coding strand G>T or G>A substitution occurred. Hence, the HGVS annotation must also be stated to provide an unambiguous description.
Recommendation for naming variants (rec 5): 5
Use haplotype translation tables to convert star (*) alleles or other legacy nomenclature to fully-specified HGVS nomenclature for each variant in the haplotype.
Naming a variant using HGVS can be time consuming and any one of many reference sequences can be used, resulting in a large number of possible names for a given variant. The workgroup developed a series of tables based on the haplotype definition tables hosted by PharmGKB, which can be used to convert the star or other nomenclature to HGVS in a standardized manner, as shown in Figure 3 . These conversion tables are available as "Reference Haplotype" lists on the Leiden Open Variation database 3.0 website (43) . The tables provide the HGVS nomenclature of each rs ID variant using the Human Genome Reference Assembly, the RefSeqGene sequence, and LRG when available. They allow for easy and standardized naming of variants of known PGx haplotypes using HGVS. Similar tables will have to be developed for other commonly tested PGx genes in order to create a uniform system. HGVS nomenclature for variants with rs IDs is also provided by the ClinVar database and can be generated using the Mutalyzer SNP converter tool (56, 57) . The nomenclature provided by Mutalyzer may need adjustment if the rs ID can refer to more than one variant, as described above. When pharmacogenetic genotypes are submitted to databases like ClinVar and LOVD, the HGVS expression for the genotype (e.g. combinations of haplotypes or rsSNPs) will also be provided in chromosome, RefSeqGene and LRG coordinates.
It is important to record not only the genotype determined for the patient, but also the exact variants and haplotypes that were tested. Current tests for PGx genes vary considerably between clinical and research laboratories. Hence alleles/haplotypes are often called based on different combinations of tested variants. Without a common understanding of which sequence variants are tested and which were found to be non-reference (variant), it is difficult to comprehend the meaning of a genotype result and compare genotypes reported by different laboratories or research studies.
The content of clinical test reports is specified by regulatory agencies and professional guidelines (58) (59) (60) (61) (62) (63) Interpretation of PGx test results requires consideration of all variants that were tested. Because PGx haplotypes may be composed of one or more variants on the same chromosome, it is important to know which variants were tested and found in the sample and which were not. Laboratories typically report only those variants that were identified in a sample, because listing results for all variant loci tested would require a much larger report format. Descriptions of the variants included in a test are needed for result interpretation when the patient is tested initially and also if the test result will be used for future patient care decisions. It is important to archive the test description, since this information might not be transmitted to electronic medical records.
The unambiguous delineation of tested variants is supported by the GTR (14) . The workgroup also discussed the importance of clearly stating in the report which rs IDs or genomic regions, as well as other variant types such as copy number variants, the test is designed to detect, how the alleles/haplotypes are determined, and which variants were successfully tested in the specific analyses. In addition to highlighting the variants that are covered by the test, laboratories should also clearly describe the limitations of the test, possibly including clinically relevant variants, haplotypes and variant types, such as CNV, that cannot be detected. This information could be included in the "assay limitations" section of the laboratory report or included in a footnote or appendix. It is also important to state assay limitations related to haplotypes that cannot be differentiated due to variant phasing or test design. Information about test design and limitations should also be made publicly accessible. Laboratories may want to consider adding a disclaimer to the report stating that observed phenotype may be different than what is predicted based on the genotype due to the presence of untested variants, drug interactions or other genetic and environmental factors.
The workgroup discussed whether laboratories should consider reporting genotypes for loci that were tested but found to be non-variant (i.e. report genotypes for reference sequence at all non-variant but tested locations). This information is crucial for understanding how the reported haplotypes were determined, which haplotypes cannot be excluded, and the limitations of the test. It may be possible to simplify these data by providing the results of all rsSNPs and other variant types, such as CNVs, that can be detected by the test and are found to be non-reference and then stating in the report that all other rsSNPs and variants that can be detected by the test (and listed in the test description) were found to be non-variant (reference). This information could be provided in a footnote or as an appendix to the report. Variants should be described using HGVS nomenclature, preferably referenced to RefSeqGene or LRG coordinates as stated above.
This detailed description of the test should inform clinicians and other professionals (current and future) about the capabilities and limitations of the test to allow full evaluation and comprehension of the test results. The workgroup recognized that although it may not be feasible to list all possible variants and haplotypes that cannot be identified by the test, some context should be given to the results so that they can be interpreted and used for care of the patient in the future.
Additional Considerations
There are a number of challenges that must be addressed and overcome before many of these recommendations can be implemented. LRG sequences need to be designated for all relevant PGx genes. Identification of a reference sequence for many of these genes can be difficult because of their highly polymorphic nature and substantial differences between populations. For example, for the VKORC1 variant rs9923231 (NG_011564.1: g.3588G>A, NM_206824.1: c.-1639G>A), A is the major allele in East Asians but G is the more common allele in other population groups. Thus, it is difficult to decide which one should be designated as the reference sequence for this gene, complicating LRG assignment.
The NCBI has multiple databases that provide identifiers for variant locations and specific alleles. The dbSNP assigns an rs ID to locations where variants less than 50 bp have been seen in one or more genomes. Ideally, the rs ID defines a unique genomic location. It is convenient to reference common PGx variants using the rs ID, however, caveats do exist. Some rsSNPs map to more than one genomic location because of sequence similarities, such as to a pseudogene or a functional gene within a family; therefore, the location of the variant being interpreted must be established. Also, not all variants, such as duplications, deletions or gene conversions that are larger than 50 base pairs are captured by dbSNP. Thus, other resources, such as dbVar (64), may also be used. The NCBI variation databases encourage feedback by a variety of stakeholders, including clinical laboratories, to prevent ambiguous variant descriptions based on its identifiers.
In PGx, it is critical to know which variants were identified and which were tested but found to be non-variant (i.e. wild-type, reference). In the example shown in Table 2 
PGx test standardization, a "Recommended Test Panel"?
As discussed above, the variants included in clinical PGx tests are not standardized. Without exception, no two tests that examined a particular PGx gene included in the GeT-RM study detected the same set of variants and/or haplotypes (39) . In addition, some tests used different combinations of variants to define the haplotypes, leading to discrepancies between platforms in the reported genotype of many samples. Differences in test design, including inconsistent inclusion of variants and/or gene copy number detection, may impact allele calling, genotype assignment and ultimately test interpretation. The workgroup recommendations presented above assist in elucidating the differences between tests, but do not prevent them from occurring.
The variants tested and methods utilized to assign haplotypes would also need to be standardized to ensure that different tests provide consistent results. The nomenclature workgroup discussed the possible creation of a list of variants that should be tested, at a minimum, for clinically relevant PGx genes, analogous to the standardization of cystic fibrosis (CF) carrier screening. (71) . On the other hand, complete DPYD deficiency is considered relatively rare (<1%) with estimates of the frequency of the *2A allele (the most common variant associated with DPYD deficiency) ranging from <0.005 to 3.5% in different populations. Since patients who are homozygous for DPYD*2A are at highest risk for severe or even fatal 5-fluorouracil or capecitabine toxicity, use of both drugs is not recommended for these patients (72) . Thus, although these variants are very rare, the severity of the adverse reaction would justify inclusion in the "Recommended Test Panel" for DPYD.
Standardized panels would enable physicians, pharmacists, researchers and other stakeholders to understand PGx test results without extensive scrutiny of the alleles included in the assay, and would provide assurance that the panels include a core set of variants considered most important for clinical utility. This is especially important when test results, originally obtained to assist selection and dosing of one drug, are later used for selection and dosing of a different drug for the same patient. Assays would be directly comparable and yield comparable results for the same sample. As with CF, laboratories could add additional alleles to their assays for research and other purposes.
The workgroup members did not reach consensus regarding the feasibility of creating PGx "Recommended Test Panel" lists. While all acknowledged the clear benefits of having such panels, many felt that such an undertaking fell outside of the scope of this particular workgroup. The European Pharmacogenetic Implementation Consortium (73), a workgroup of the IFCC, is currently developing a list of PGx alleles that should be included in clinical tests. It can be argued that determining a "Recommended Test Panel" for pharmacogenes is even more difficult than for Mendelian diseases. Additionally, allele function in in vitro models may not be equivalent to clinical phenotype, and allele function can be substrate (drug), or drug concentration-dependent. Although an allele can be extremely rare in the general population, it can be frequent in another population or in a phenotypically selected group of patients (e.g. those with side effects on specific drugs). Therefore, the question arises, if the allele is rare, but unequivocally affects function, should it be included in a test panel?
Additionally, a "Recommended Test Panel" would require periodic re-evaluation as novel variants are found, characterized and new insights into genotype-phenotype relationships are identified. Each association will need to be evaluated by the same criteria to assess importance and added to the "Recommended Test Panel" if the criteria are met. In some cases, further research may show that an allele previously on the "Recommended Test Panel" list no longer meets the required criteria. A plan for routine evaluation of "Recommended Test Panel" would be critical.
Conclusion and Future Plans
The PGx Nomenclature Workgroup has developed recommendations to standardize the way pharmacogenetic variants are described and reported. These recommendations, together with those currently being developed to standardize phenotype inference (74) , will make PGx test results more transparent and will harmonize PGx testing with the broader field of genetic testing.
One important aim of this manuscript is to link existing, non-standard variant descriptions and reporting to existing standards like the HGVS nomenclature (28) . Clinicians and others who are familiar with the star nomenclature might find the HGVS nomenclature to be tedious or hard to understand. To address this issue, the workgroup suggests that laboratory reports can include common or familiar names in parenthesis along with the HGVS notation. In addition, this group is currently developing HGVS conversion tables for pharmacogenes that will allow easy translation between the recommended nomenclature and those notations currently in use.
The workgroup is proposing these changes with the expectation that they will be considered by organizations including gene variation databases, scientific journals, regulatory agencies, and professional societies for the creation of policies, guidelines and recommendations. Following publication of these recommendations, the workgroup plans to meet with representatives of relevant professional societies, PGx gene nomenclature committees, and other groups, some of whom have begun to address these issues to explore these ideas further.
The workgroup hopes that these proposed recommendations will be discussed and ultimately adopted by the PGx community. Although some ideas described may appear controversial, these recommendations are intended to lead to a more standardized approach to testing and reporting of PGx test results. Ultimately, standardization will enhance clinical interpretation of PGx associations, accelerating the implementation of pharmacogenetics into routine clinical practice.
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